全球首个无进展生存期、总生存期双获益 科伦博泰TROP2 ADC实现肺癌二线治疗突破

每日经济新闻
Oct 20, 2025

破解EGFR突变非小细胞肺癌(NSCLC)的EGFR-TKI耐药,是新一代疗法的共同课题。  近日,科伦博泰在2025年欧洲肿瘤内科学会年会上,公布了TROP2 ADC芦康沙妥珠单抗(sac-TMT)的一项III期临床研究数据。  这项研究数据显示,芦康沙妥珠单抗成为全球首个在EGFR突变NSCLC二线治疗中取得PFS(无进展生存期)与OS(总生存期)双重获益的药物,有望填补当前该领域巨大的治疗...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10